Bristol Myers Squibb's Camzyos Shows Promising Results in Phase 3 Trial for Adolescent Obstructive Heart Disease Patients.

Bristol Myers Squibb's Phase 3 SCOUT-HCM trial for Camzyos in adolescents with obstructive heart disease met its primary endpoint, showing improved obstruction. The study also met several secondary endpoints tied to disease symptoms and functional measures. Safety findings were in line with the adult profile of Camzyos, with no new safety signals in the adolescent population. Bristol Myers Squibb plans to present detailed data at a future medical meeting and discuss findings with regulators.